FN

Paragon 28 IncNYSE FNA Stock Report

Last reporting period 30 Jun, 2024

Updated 12 Nov, 2024

Last price

Market cap $B

0.556

Micro

Exchange

XNYS - New York Stock Exchange, Inc

FNA Stock Analysis

FN

Uncovered

Paragon 28 Inc is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

-26/100

Low score

Market cap $B

0.556

Dividend yield

Shares outstanding

77.771 B

Paragon 28, Inc. engages in operation of an orthopedic foot and ankle company. The company is headquartered in Englewood, Colorado. The company went IPO on 2021-10-21. The firm develops, distributes, and sells medical devices in the foot and ankle segment of the orthopedic implant marketplace. Its products and product families include plates and plating systems, screws, staples, and nails aimed to address all major foot and ankle procedures including fracture fixation, hallux valgus, which includes bunion and hammertoe, ankle, progressive collapsing foot deformity (PCDF) or flatfoot, charcot foot and orthobiologics. To treat these painful, debilitating or even life-threatening conditions, it provides a portfolio of solutions that includes surgical implants and disposables, as well as surgical instrumentation. Its commercial footprint spans across all 50 states of the United States and 23 other countries. In the United States, the Company primarily sells to hospitals and ambulatory surgery centers through a network of primarily independent sales representatives, the majority of whom are exclusive.

View Section: Eyestock Rating